Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where U. Jeschke is active.

Publication


Featured researches published by U. Jeschke.


Histochemistry and Cell Biology | 2000

Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors

Christina Herrnring; Toralf Reimer; U. Jeschke; Josef Makovitzky; Karolin Kruger; Bernd Gerber; Dieter Kabelitz; K Friese

Abstract Apoptosis-inducing ligands such as Fas ligand (FasL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) have been found to play an important role in cell regulation. Different malignant tumors show an altered expression of these ligands and their respective receptors compared to normal tissues. The purpose of this study was therefore to investigate expression of TRAIL, FasL, and its receptor Fas on protein and mRNA levels in breast carcinomas (n=40), fibroadenomas (n=7), and normal breast tissues (n=5). Immunohistochemical reaction demonstrated that FasL was strongly expressed in breast cancer tissues (34/40) while only one fibroadenoma and one normal breast tissue reacted weakly positive for FasL. All fibroadenomas and normal breast tissues as well as the majority of breast cancer tissues expressed Fas on protein level. Quantitative RT-PCR analysis detected high expression of FasL mRNA in breast cancer tissues and fibroadenomas, whereas fibroadenomas showed the highest Fas mRNA copy numbers, followed by breast cancer tissues and normal breast tissues (P<0.05). Compared to FasL expression, TRAIL could be detected in less breast cancer tissues on protein level (21/40) and was found in only one fibroadenoma and none of the normal breast tissues. Thus, it can be concluded that malignant breast tumors show an altered expression of the two apoptosis-inducing ligands FasL and TRAIL.


Molecular Biotechnology | 2000

Absolute quantification of human chorionic gonadotropin-β mRNA with TaqMan™ detection

Toralf Reimer; Dirk Koczan; Volker Briese; K Friese; Dagmar-Ulrike Richter; Hans-Jürgen Thiesen; U. Jeschke

We describe a reverse transcriptase-polymerase chain reaction (RT-PCR) for determination of human chorionic gonadotropin-β (HCGβ) mRNA copies using the TaqMan™ system. To evaluate our quantitative assay, we analyzed HCGβ transcripts of all protein coding genes (HCGβ 5, 3, 8, and 7) in human RNA panels of different normal tissues and in glycodelin-A-stimulated trophoblast cell cultures. Absolute quantification using HCGβ TaqMan probe was found to be highly reproducible. Our study of RNA panels confirms recently published results that expression of HCGβ transcripts is a common feature of a great variety of different normal tissues. High levels of HCGβ mRNAs (>1.000 molecules per 200 ng RNA) were detected in placenta, uterus, and testis. An increase of HCGβ mRNA expression (1.7-fold) was detected at 150 µg/mL glycodelin-A treatment in trophoblast cell culture. Time-dependence study showed that the increase in HCGβ mRNA level was evident at 60 min after glycodelin-A treatment. In summary, we have developed a highly sensitive one-tube, one-enzyme quantitative RT-PCR system that is time-saving and avoids postamplification procedures.


Maturitas | 1999

Differential diagnosis of peri- and postmenopausal ovarian cysts.

Toralf Reimer; Bernd Gerber; Heiner Müller; U. Jeschke; Annette Krause; K Friese

OBJECTIVES To test the value of preoperative and intracystic parameters in the differential diagnosis of ovarian cysts. METHODS Criteria for admission of 58 patients were age > 47 years, complete history, detection of CA 125 serum level, and ultrasound findings. Tumor markers (CA 125, cancer-associated serum antigen (CASA), CA 72-4), hormones (estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH)), epidermal growth factor (EGF) receptor and c-erb B-2 amplification rate were detected in cyst fluid. RESULTS Of the 58 subjects, 9 (15.4%) had functional cysts, 37 (63.8%) had benign tumors and 12 (20.8%) had malignant tumors. No functional ovarian cyst presented as echoic or multilocular cyst sonographically. The serum CA 125 values demonstrated significant differences between the non-malignant and malignant patient groups (P < 0.0005). The majority (63.8%, n = 37) of ovarian cysts were obtained at laparotomy, whereas only 36.2% (n = 21) were laparoscopically operated. The cyst fluid levels of FSH (P < 0.005) and LH (P < 0.05) were significantly lower in the functional group than in the benign or malignant group. Malignant cysts were significantly different from non-malignant cysts regarding low E2 (P < 0.01), high FSH (P < 0.05) and CASA (P < 0.02) values. There were no significant correlations between EGF receptor (P = 0.14) and c-erb B-2 (P = 0.06) gene amplification rates and malignant histology. CONCLUSIONS Simple ovarian cysts combined with normal serum CA 125 levels are candidates for conservative follow-up or laparoscopy. The serum CA 125 is a powerful marker for prediction of histology in postmenopausal ovarian cyst. Laparoscopic surgery may be considered in patients with multilocular sonographic findings and normal CA 125 serum level. Combining serum CA 125 levels with cyst fluid parameters (E2, FSH, CASA) improves the sensitivity and specificity in predicting malignancy.


Histochemistry and Cell Biology | 2002

Expression of the Thomsen-Friedenreich antigen and of its putative carrier protein mucin 1 in the human placenta and in trophoblast cells in vitro

U. Jeschke; Dagmar-Ulrike Richter; A. Hammer; Volker Briese; K Friese; Uwe Karsten


Histochemistry and Cell Biology | 2000

Immunohistochemical analysis of steroid receptors and glycodelin A (PP14) in isolated glandular epithelial cells of normal human endometrium

Ioannis Mylonas; Runa Speer; Josef Makovitzky; Dagmar Ulrike Richter; Volker Briese; U. Jeschke; K Friese


Anticancer Research | 2005

Normal and Malignant Human Endometrium Express Immunohistochemically Estrogen Receptor Alpha (ER-α), Estrogen Receptor Beta (ER-β) and Progesterone Receptor (PR)

Ioannis Mylonas; U. Jeschke; Naim Shabani; Christina Kuhn; S. Kriegel; Markus S. Kupka; Klaus Friese


Anticancer Research | 2003

Immunohistochemical expression of steroid receptors and glycodelin A in isolated proliferative human endometrial glandular cells after stimulation with tamoxifen and phytoestrogens (genistein and daidzein).

Ioannis Mylonas; U. Jeschke; Josef Makovitzky; Winkler L; Dagmar-Ulrike Richter; Klaus Friese; Briese


Anticancer Research | 2003

Immunohistochemical expression of the tumour marker CA-125 in normal, hyperplastic and malignant endometrial tissue.

Ioannis Mylonas; Josef Makovitzky; Dagmar-Ulrike Richter; U. Jeschke; Briese; Klaus Friese


Anticancer Research | 2003

Effects of phytoestrogens on the trophoblast tumour cell lines BeWo and Jeg3.

D. Plessow; J. Waldschläger; Dagmar-Ulrike Richter; U. Jeschke; G. Bruer; Volker Briese; Klaus Friese


Anticancer Research | 2000

Expression of the Thomsen-Friedenreich (TF) antigen in the human placenta

Dagmar-Ulrike Richter; U. Jeschke; Josef Makovitzky; Steffen Goletz; Uwe Karsten; Volker Briese; Klaus Friese

Collaboration


Dive into the U. Jeschke's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

K Friese

University of Rostock

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Uwe Karsten

Max Delbrück Center for Molecular Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge